DR. MARK IBSEN, MD, PUTTING HIS LIFE, WEALTH, AND FREEDOM ON THE LINE: THE POWER GRAB HOW PHARMACISTS HAVE BECOME THE GREATEST THREAT TO HEALTHCARE. (Advanced c.e. 5/25/25 edition-fbp-#25)

PROSECUTORIAL DATA MINING METHODOLOGY A CASE OF DISEASE VS. DATA

from youarewithinthenorms.com

NORMAN J CLEMENT RPH., DDS, NORMAN L. CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., INC., SPIRIT OF REV. IN THE SPIRIT OF WALTER R. CLEMENT BS., MS, MBA. HARVEY JENKINS, MD, PH.D., IN THE SPIRIT OF C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., M.B.A., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., EVELYN J. CLEMENT, WALTER F. WRENN III., MD., JULIE KILLINGSWORTH, RENEE BLARE, RPH, DR. TERENCE SASAKI, MD LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, WILLIE GUINYARD BS., JOSEPH WEBSTER MD., MBA, BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., RICHARD KAUL, MD., IN THE SPIRIT OF LEROY BAYLOR, JAY K. JOSHI MD., MBA, AISHA GARDNER, ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS

A regal figure wearing ornate religious attire and a crown, holding a scepter and scales, symbolizing justice and wisdom, against a backdrop of technical schematics and glowing text that reads 'FAITH' and 'Reason'. — EXAULTED COPORATE BISHOP PHARMD ESQ

Bias medical algorithms

This article, submitted to the Florida Board of Pharmacy, was used as part of a series of studies for 12 hours continuing education credits originally published on May 05, 2025, that examine the ethical and practical dangers of utilizing machine learning and predictive modeling within Prescription Drug Monitoring Programs to police opioid distribution. The author argues that these automated systems suffer from inherent bias, as they prioritize the detection of fraud and abuse while overlooking the legitimate needs of chronic pain patients. By utilizing unvalidated algorithms and non-transparent methodologies, these tools function as surveillance mechanisms that can lead to the denial of essential care and the professional intimidation of physicians. Ultimately, the text serves as a critique of the “power grab” by corporate pharmacy entities and government agencies, advocating for greater data transparency and a return to patient-centered medical protocols.

THE POWER GRAB

exploring the complexities and controversies surrounding Prescription Drug Monitoring Programs (PDMPs)

LAW ENFORCEMENT AND MEDICAL PROTOCOLS: HOW AI Risk scores are overriding YOUR doctor

This article explores the complexities and controversies surrounding Prescription Drug Monitoring Programs (PDMPs), particularly their reliance on machine learning and predictive modeling to identify potential drug abuse and diversion.

A key theme is the inherent bias in these systems, as they are primarily designed to detect behaviors associated with harm, fraud, waste, and abuse, while often failing to account for appropriate opioid use, patient benefits, or positive outcomes.

The source highlights concerns that these algorithms, and tools like NarxCare, may be misbranded medical devices due to a lack of validation for their predictive scores and inadequate transparency regarding their methodologies, potentially leading to harmful outcomes for patients and healthcare providers.

Additionally, the youtube video presentation “I’m Only Human touches upon the historical context of PDMP development, the influence of groups advocating for stricter opioid policies, and the potential for PDMP data sharing with third-party payers to reduce costs but also raise privacy and data misuse concerns.

Law Enforcement and Medical Protocols: A Critical Overview

PAIN CARE ADVOCATE JAMIE SANCHZ DISCUSSES WITH PAIN CARE ADVOCATE & PHARMACIST STEVE ARIENS THE TYRANNY OF PHARMACIST WITHOLDING TREATMENT AND THE PROLIFERATION OF PAIN CARE DENIAL AND SUFFERING

THE CORPORate overlords ARE willing to sell out the truth

A letter from Walgreens dated April 9, 2025, informing a patient about the discontinuation of controlled substance prescriptions from their prescriber, Mark Ibsen, MD, due to internal policy changes. — Walgreens Withhold Pain Care Treatment of Dr. Mark Ibsens’s Patients without any supportive foundation or facts

AI (algt*) =AS

Ronald W. Chapman II, JD, LLM President and Chief Executive Officer, Chapman Law Group, Troy, Michigan

Attorney Ron Chapman recently articulated

” As the only Marine in my unit with a law degree and a deep appreciation for civil liberties, Palantir’s capacity for enabling civil rights abuses stood out to me immediately. We outsourced critical decisions to a proprietary algorithm…When it worked, it unquestionably saved lives.

But you become addicted to that sense of “knowing the future,” even when it’s just sophisticated pattern recognition. We believed we were chasing the Taliban, at least.

Certainly a far cry from prescribing medications. Yet years later, when Palantir’s sales teams stormed government contracting offices bragging that their system could replicate its counterinsurgency successes in Medicare fraud detection, I was deeply alarmed.

AI (algt*) =AS

PALANTIR

Conclusion:

PDMPs represent a complex and evolving tool in addressing prescription drug abuse and improving patient safety. While evidence indicates their potential effectiveness in specific areas like reducing doctor shopping and informing prescribing, significant concerns remain regarding their use as surveillance tools, the potential for algorithmic bias, and the lack of standardization in key metrics.

“SCORE TOO HIGH-NOT CANCER PAIN”

Future efforts should focus on enhancing data quality, ensuring transparency in algorithmic processes, establishing best practices for data sharing with third-party payers with appropriate safeguards, and continuing to evaluate the impact of PDMPs on both public health and individual patient care.

The nuances in calculating MME per day and the potential for misclassification highlight the need for careful consideration in policy and enforcement related to opioid prescribing.

DONATE LEGAL DEFENSE

OR SEND

TO CASH APP:$docnorm

ZELLE 3135103378